Chemotherapy-free treatment targeting fusions and driver mutations in wild-type pancreatic ductal adenocarcinoma, a case series.

Background: wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in a real-world setting, to date, is less established.

Objectives: The aim of our study was to review our institutional database to identify the prevalence of actionable genomic alterations in patients with -WT tumors and to evaluate the therapeutic impact of matched targeted therapy in these patients.

Pancreatic Adenocarcinoma with Co-Occurrence of and Mutations: Case Report and Literature Review.

Introduction: Mutation in oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in nearly 90% of patients with PDAC. () mutation is rare in PDAC and is mostly present in the absence of mutation. Co-occurrence of and mutations is extremely rare, and the value of EGFR inhibition in these cases is unknown.